• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Unicycive Therapeutics Inc.

    11/13/24 4:52:02 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UNCY alert in real time by email
    SC 13G 1 walleye-uncy093024.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    UNICYCIVE THERAPEUTICS, INC.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    90466Y103

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  90466Y103
     SCHEDULE 13G
    Page 2 of 6 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Walleye Capital LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Minnesota
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    5,000,000
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    5,000,000
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    5,000,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.30%
    12
    TYPE OF REPORTING PERSON
     
    IA

     


     

     

    CUSIP No.  90466Y103
     SCHEDULE 13G
    Page 3 of 6 Pages

     

    Item 1.(a) Name of Issuer

    UNICYCIVE THERAPEUTICS, INC.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    4300 El Camino Real, Suite 210

    Los Altos, CA 94022

    Item 2.(a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:

    Walleye Capital LLC, a Minnesota limited liability company

    315 Park Ave. South

    New York, NY 10010

      

    Item 2.(d) Title of Class of Securities

    Common Stock, par value $0.001 per share

     

    Item 2.(e) CUSIP No.:

    90466Y103

     

    CUSIP No.  90466Y103
     SCHEDULE 13G
    Page 4 of 6 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No.  90466Y103
     SCHEDULE 13G
    Page 5 of 6 Pages

     

     

    Item 4. Ownership

    Information with respect to the Reporting Person’s ownership of the Common Stock, par value $0.001 per share as of September 30, 2024, is incorporated by reference to items (5) - (9) and (11) of the cover page for the Reporting Person.

    The amount beneficially owned by the Reporting Person is determined based on 94,356,212 shares of Common Stock, outstanding as of August 14, 2024.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No.  G26735103
     SCHEDULE 13G
    Page 6 of 6 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 13, 2024

     

     

     

     

    Walleye Capital LLC

           
      By:  /s/ Thomas Wynn
        Thomas Wynn, Global Chief Compliance Officer
           

     

           
    Get the next $UNCY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UNCY

    DatePrice TargetRatingAnalyst
    4/21/2025$6.00Buy
    Guggenheim
    4/4/2024$9.00Overweight
    Piper Sandler
    8/9/2021$13.50Buy
    Roth Capital
    More analyst ratings

    $UNCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

      - Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025 - New data from patient surveys and patient-reported outcomes studies highlight adherence challenges for patients with hyperphosphatemia on dialysis and emphasize the market potential of OLC LOS ALTOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial

      5/14/25 7:15:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

      LOS ALTOS, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, at 2:15 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To request a 1x1 meeting with management, please contact your Needham representative. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments f

      4/1/25 7:00:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update

            - Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025 - Commercial planning in preparation for anticipated commercial launch of OLC in late 2025 LOS ALTOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2024, and provided a business update. "2025 is positioned to be a transformational year for Unicycive, with the near-term potential for

      3/31/25 7:00:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UNCY
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.

      SCHEDULE 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      5/15/25 4:56:41 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.

      SCHEDULE 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      5/15/25 4:39:09 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)

      5/14/25 8:01:50 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UNCY
    Leadership Updates

    Live Leadership Updates

    See more
    • Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD

      LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced the appointment of Sara Kenkare-Mitra, PhD to the Company's Board of Directors, effective September 6, 2023. As a veteran of the biotech and pharmaceutical industry, we believe Sara's leadership and experience in drug development spanning more than 25 years will significantly help bolster Unicycive's future growth. "We are thrilled to welcome Dr. Kenkare-Mitra to our Board of Directors and know that her extensive drug development and corporate leadersh

      9/6/23 7:03:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy

      LOS ALTOS, Calif., Oct. 26, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Douglas Jermasek as Executive Vice President, Corporate Strategy. In this role, Mr. Jermasek, a seasoned healthcare professional, will have responsibility for Unicycive's corporate and commercial strategy and business development activities. Doug has spent the majority of his career focused on drugs for treatment of kidney diseases"With a career spent in heal

      10/26/21 7:30:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UNCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

      SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      11/14/24 7:13:38 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

      SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      11/14/24 7:01:14 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

      SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      11/14/24 5:46:12 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UNCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Unicycive Therapeutics with a new price target

      Guggenheim initiated coverage of Unicycive Therapeutics with a rating of Buy and set a new price target of $6.00

      4/21/25 8:39:22 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Unicycive Therapeutics with a new price target

      Piper Sandler initiated coverage of Unicycive Therapeutics with a rating of Overweight and set a new price target of $9.00

      4/4/24 8:18:34 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital initiated coverage on Unicycive Therapeutics with a new price target

      Roth Capital initiated coverage of Unicycive Therapeutics with a rating of Buy and set a new price target of $13.50

      8/9/21 9:57:19 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UNCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Aggarwal Gaurav converted options into 1,400,000 shares (SEC Form 4)

      4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)

      2/19/25 11:55:27 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Aggarwal Gaurav converted options into 5,500,000 shares (SEC Form 4)

      4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)

      10/10/24 5:15:20 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Townsend John

      4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)

      8/14/24 4:15:20 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UNCY
    Financials

    Live finance-specific insights

    See more
    • Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

      - Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025 - New data from patient surveys and patient-reported outcomes studies highlight adherence challenges for patients with hyperphosphatemia on dialysis and emphasize the market potential of OLC LOS ALTOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial

      5/14/25 7:15:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update

            - Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025 - Commercial planning in preparation for anticipated commercial launch of OLC in late 2025 LOS ALTOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2024, and provided a business update. "2025 is positioned to be a transformational year for Unicycive, with the near-term potential for

      3/31/25 7:00:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

      – OLC New Drug Application (NDA) Accepted by the FDA with a PDUFA Target Action Date of June 28, 2025– – Commercial Planning in Progress for 2025 Launch – – Late Breaker Poster Presentation on OLC at ASN Kidney Week – – Successful Completion of UNI-494 Phase 1 Trial – LOS ALTOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY) (the "Company" or "Unicycive"), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended September 30, 2024, and provided a business update. "We are pleased with the

      11/13/24 7:15:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care